KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Liabilities (2017 - 2025)

Moderna (MRNA) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $281.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $281.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $281.0 million, a N/A change, with the full-year FY2024 number at $267.0 million, up 4.3% from a year prior.
  • Other Non-Current Liabilities was $281.0 million for Q3 2025 at Moderna, up from $274.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $281.0 million in Q3 2025 to a low of $2.0 million in Q1 2021.
  • A 5-year average of $199.2 million and a median of $259.0 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 2433.33% in 2021, then rose 4.3% in 2024.
  • Moderna's Other Non-Current Liabilities stood at $76.0 million in 2021, then surged by 77.63% to $135.0 million in 2022, then surged by 89.63% to $256.0 million in 2023, then grew by 4.3% to $267.0 million in 2024, then grew by 5.24% to $281.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Other Non-Current Liabilities are $281.0 million (Q3 2025), $274.0 million (Q1 2025), and $267.0 million (Q4 2024).